Plus, news about DBV, Double Point Ventures and Lumos:
Eccogene’s $60M milestone from AstraZeneca: The payment arrived after Eccogene met several milestones, including dosing the first patient in a Phase 2b program. The companies inked a deal a year ago to develop candidates for obesity and comorbidities like type 2 diabetes, with AstraZeneca paying $185 million upfront and up to $1.8 billion in milestones. — Jaimy Lee
Bristol Myers Squibb makes $50M milestone payment to Evotec: The companies first partnered in 2018 and expanded their work developing molecular glue degraders in 2022. — Jaimy Lee
DBV gets FDA feedback on peanut allergy patch: The penny stock company said it informally agreed to a surrogate endpoint for a potential accelerated approval for its Viaskin treatment for toddlers aged one to three years old. DBV expects a confirmatory study to be up and running by the second quarter of 2025 before it submits a BLA. DBV’s stock price $DBVT was up about 35% in trading on Wednesday. — Max Gelman
Double Point Ventures takes Lumos private: About five years after going public via reverse merger, Lumos Pharma has agreed to a takeover for $4.25 per share $LUMO. Shareholders can eventually get more money if certain milestones are met. The company also said it aligned with the FDA on a Phase 3 trial in pediatric growth hormone deficiency. — Kyle LaHucik